DHR
ACCE-researchedDanaher Corporation Common Stock
Healthcare · Diagnostics & Research · NYSE · United States
$211.81-0.32%
Market cap $148.9BNext earnings 2026-10-20Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$211.81+0.0%
confidence-weighted across 5 of 6 models
Now $211.81
$211.81
$90.80$198.77
TrimSilver65
Price vs fair value
40.0% above
-28.6% to fair value
ACCE score
62
out of 100
Analysts
88% buy
25 covering
P/E
37.8x
forward 22.8x
1-year return
+8.5%
Dividend yield
0.68%
Unlock the ACCE read
INVESTOROverview
⚠ Investor warnings · 3 flags
- moderateMomentum score still weakACCE Momentum score is 38/100, indicating weak price/trend momentum despite recent 10-point score recovery from 41.
- moderateSharp QoQ revenue declineQuarter-over-quarter revenue dropped -13.0%, signalling potential near-term demand softness beyond the modest +3.7% YoY growth.
- moderateROE low for valuation paidROE of only 7.1% is thin for a stock trading at 38.6x trailing P/E and 21.7x EV/EBITDA, suggesting capital inefficiency post-Veeva spin.
Reports in 29 days, last quarter beat by 0.1%.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
+11.2% · 1Y
Valuation
INVESTORFull valuation engine INVESTOR FEATURE
Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORQuality and conviction INVESTOR FEATURE
The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
Bullish88% buy · 25 covering analysts
● Strong buy 18● Buy 4● Hold 3● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROSmart money tracking PRO FEATURE
Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
This stock Peer Peer median weaker → stronger
P/Ebetter than 17% of peers
low 0.0x37.8xhigh 106.5x
ROEbetter than 33% of peers
low -13%8%high 23%
Div yieldbetter than 83% of peers
low 0.0%0.7%high 0.9%
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc Common Stock | $240.9B | 35.1 | 13.5% | 0.74 | 0.3% | - | Compare |
| NTRA | Natera Inc. Common Stock | $53.2B | - | -12.5% | 0.05 | 0.0% | - | Compare |
| LONN.SW | Lonza Group | $46.2B | 35.2 | 12.9% | 0.46 | 0.9% | - | Compare |
| A | Agilent Technologies Inc. Common Stock | $44.1B | 30.9 | 21.0% | 0.50 | 0.7% | - | Compare |
| IQV | IQVIA Holdings Inc. Common Stock | $43.9B | 33.1 | 22.8% | 2.42 | 0.0% | - | Compare |
| WAT | Waters Corporation Common Stock | $41.4B | 106.5 | 1.9% | 0.73 | 0.0% | - | Compare |
Sector report card
Where DHR ranks against its sector peers on each metric.
Computing percentiles…
News and Record
Reports in 29 days, last quarter beat by 0.1%.
Press releases mentioning this company
- PR Newswire•Sep 15, 2026Danaher Announces Quarterly Dividend
- GlobeNewswire•Sep 15, 2026High Content Screening Market Forecasts Growth from $3.37B (2026) to $6.58B by 2032, Profiling Thermo Fisher, Danaher, GE HealthCare & 27 Other Key Players
- GlobeNewswire•Sep 15, 2026Single-Use Bioreactors Market by Product, Type, Cell Type, Molecule, Process Mode, Application, Competition, Region - Global Forecast to 2031
9 more press releases · full archive on Investor+.INVESTOR
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.
PRO
Recent performance
1 week
+5.8%
1 month
+0.1%
3 months
+19.6%
6 months
+11.9%
YTD
-7.5%
1 year
+8.5%
SEC filings
40 filings
August 2026
Aug 24
Form 4Insider transactionPeriod 2026-08-21
Aug 6
Form 4Insider transactionPeriod 2026-08-04
Aug 6
Form 4Insider transactionPeriod 2026-08-04
37 more filings + AI summaries on Investor+.INVESTOR